Syntis Bio: Enzyme Substitution Therapy

  • Home
  • Syntis Bio: Enzyme Substitution Therapy

Syntis Bio is developing an enzyme substitution therapy for patients with Homocystinuria due to CBS deficiency (Classical HCU). Learn more about their therapy pipeline here

 

In June 2024, Syntis Bio acquired the Codexis HCU program, CDX 6512. Upon acquisition, the program is now referred to as SYNT-202.

June 11, 2024

Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine

August, 2023

An orally administered enzyme therapeutic for homocystinuria that suppresses homocysteine by metabolizing methionine in the gastrointestinal tract

July 20, 2023

Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026

January 26, 2022

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Classical Homocystinuria

November 22, 2021

Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

Pages

© 2016 Enigma Theme|Theme Developed By Weblizar Themes

Verified by ExactMetrics